8月11日 - ** AbCellera Biologics（ABCL.O）股价在盘后交易中下跌3.5%，至9.42美元，该公司正寻求融资
** 这家加拿大生物技术公司 (link) 启动2亿美元融资计划，包括股票和预先注资的认股权证
** 计划将净募集资金用于研发、推进内部管线（包括领头临床项目ABCL635）的临床进展，以及其他用途
** 周一，ABCL股价飙升35%，此前该公司 (link) 称其更年期治疗药物ABCL635在中期试验中减轻了潮热症状
** 周二收盘时股价上涨4.5%，报9.76美元，年内累计涨幅近三倍
** 杰富瑞、摩根大通、坎托、瑞银和蒙特利尔银行将担任此次拟议发行的联合簿记管理人
** 该公司流通股约为3.066亿股，市值约为30亿美元
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.